tPA Inhibitors
1 drugsAbout tPA
Tissue plasminogen activator (tPA) is a serine protease that catalyzes plasminogen to plasmin, dissolving fibrin clots and playing a key role in thrombolysis. Its primary function is to restore blood flow in conditions like acute ischemic stroke.
TPA is a therapeutic target for thrombosis management due to its role in breaking down blood clots. Currently, there is no genetic evidence data available linking tPA to specific diseases.
TNKASE (alteplase) is the only FDA-approved drug targeting tPA, developed by Roche. It is a biologic (other) and was approved in 2000 for one indication.
Top tPA Drugs
Roche is the only company with an approved drug targeting tPA.
The market is highly concentrated, indicating potential entry barriers or limited investment in this target.
tPA Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets tPA, using enzyme modality.
The lack of modality diversity suggests an opportunity for novel small molecule or antibody-based tPA modulators.
tPA Clinical Trials 75 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on tPA. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 0 | 0 | 2 | - |
| Phase 2 | 23 | 13 | 3 | 7 | 81% |
| Phase 3 | 40 | 15 | 5 | 20 | 75% |
| Phase 4 | 10 | 3 | 1 | 6 | 75% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved tPA drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting tPA. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
tPA Drug Approval Timeline (2000 - 2000)
The only approved drug, TNKASE, was approved in 2000.
The lack of recent approvals suggests a saturated market or challenges in developing new tPA-targeting therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 44 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on tPA. A trial counts if an approved drug acting on tPA is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.